<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979993/" ref="ordinalpos=2741&amp;ncbi_uid=6008778&amp;link_uid=PMC3979993" image-link="/pmc/articles/PMC3979993/figure/F6/" class="imagepopup">Figure 6.  From: Andrographolide Suppress Tumor Growth by Inhibiting TLR4/NF-?B <span class="highlight" style="background-color:">Signaling</span> Activation in Insulinoma. </a></div><br /><div class="p4l_captionBody"><b> TLR4/NF-ÎºB signaling pathway is the dominant functional target of andrographolide</b>. (A) TLR4 deficient could only slightly inhibit the expression of p65 and cannot suppress the expression of MyD88. (B) The inhibition of MyD88 result the reduction of p65 but not TLR4 (C) p65 deficient could inhibit the expression of MyD88 but not TLR4. (D) The inhibition of TLR4, MyD88 and p65 can both suppressed cell proliferation. n=12, * P &lt; 0.05, ** P &lt; 0.01 and *** P &lt; 0.001.</div></div>